Tatiana A Mishchenko, Oluwabukolami J Olajide, Ekaterina N Gorshkova, Maria V Vedunova, Dmitri V Krysko
{"title":"Regulated cell death modalities: breaking resistance of temozolomide glioblastoma therapy.","authors":"Tatiana A Mishchenko, Oluwabukolami J Olajide, Ekaterina N Gorshkova, Maria V Vedunova, Dmitri V Krysko","doi":"10.1016/j.trecan.2025.01.007","DOIUrl":null,"url":null,"abstract":"<p><p>Temozolomide (TMZ), the standard first-line chemotherapy for glioblastoma multiforme (GBM), has been a cornerstone of treatment despite its known limitations. We propose critically assessing TMZ's potential to induce multiple regulated cell death modalities and leveraging their immunogenic properties to develop novel strategies for overcoming the resistance of GBM and enhancing its therapy.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3000,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.trecan.2025.01.007","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Temozolomide (TMZ), the standard first-line chemotherapy for glioblastoma multiforme (GBM), has been a cornerstone of treatment despite its known limitations. We propose critically assessing TMZ's potential to induce multiple regulated cell death modalities and leveraging their immunogenic properties to develop novel strategies for overcoming the resistance of GBM and enhancing its therapy.
期刊介绍：
Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine.
Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
